1271 - Comparison of Tocilizumab and TNF Inhibitor Therapy in Rheumatoid Arthritis

Monday, November 7, 2011: 9:00 AM-6:00 PM
Hall F2 - Poster Hall (McCormick Place West)
Jörg Kaufmann, Rheumatologist, Ludwigsfelde, Germany, Susanne Seel, Ambulant Centres f. Rheumatology, Ludwigsfelde, Germany and Anne-Eve Roske, Roche Pharma AG, Grenzach-Wyhlen, Germany
Presentation Number: 1271

Comparison of Tocilizumab and TNF Inhibitor Therapy in Rheumatoid Arthritis

 

Background/Purpose:

The combination of a biologic DMARD (bDMARD) with methotrexate (MTX) is regarded as the gold standard for patients having not adequately responded to a conventional DMARD (cDMARD) therapy. There are no results from randomized controlled studies comparing different bDMARDs.

Aim is to compare the effectiveness of TNF inhibitors with Tocilizumab with respect to clinical and sonographic parameters.

 

Methods:

Data from 98 patients in whom bDMARD (TNF inhibitor or Tocilizumab) therapy had been initiated between September 2009 and September 2010 were retrospectively analysed. Selection criteria included confirmed diagnosis of RA and age >18 years. Patients had to be on their first bDMARD. Patients were examined sonographically at baseline and every 3 months using the US-7 score. The DAS28 score was recorded every 3 months.

Results:

The Tocilizumab and TNF inhibitor cohorts consisted of 40 and 48 patients, respectively. Both groups were comparable in age, disease duration and gender distribution.

The following table shows the mean values for the DAS28 baseline and after 3, 6, 9 and 12 months compared to the biologics, which differ in their mode of action. The horizontal line marks the DAS28 remission threshold at 2.6.

 

 

 

Conclusion:

Tocilizumab shows in the groups both clinically and sonographically significantly better effectiveness compared to TNF inhibitors. Prospective randomized controlled studies have been initiated to confirm these results.

 


Keywords: remission, rheumatoid arthritis, treatment, tocilizumab and ultrasound

Disclosure: J. Kaufmann, None; S. Seel, None; A. E. Roske, None.